Prodrug Conversion to Ribavirin Pathway

The enzymatic and metabolic pathway responsible for converting prodrugs (notably viramidine) into ribavirin, a broad-spectrum antiviral agent. Key enzymes involved include adenosine deaminase (ADA), adenosine kinase, and cytosolic 5′-nucleotidase II. The conversion of viramidine to ribavirin by ADA is followed by phosphorylation to active metabolites (mono-, di-, and triphosphate forms). Ribavirin's mechanisms of action include inhibition of viral RNA polymerases, disruption of mRNA capping, depletion of GTP pools, and interaction with eIF4E. This pathway is critical for the therapeutic efficacy of ribavirin against a wide range of viruses, including hepatitis C virus, influenza virus, and coronaviruses.

Other names

Viramidine to Ribavirin ConversionRibavirin Prodrug ActivationADA-mediated Ribavirin ProductionRibavirin Metabolic Pathway

The prodrug conversion to ribavirin is a crucial step for achieving the antiviral effects of ribavirin. After conversion, ribavirin acts through several mechanisms including inhibition of viral RNA polymerases, disruption of mRNA capping, depletion of GTP pools, and interaction with eIF4E, ultimately disrupting viral replication and protein synthesis.